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Vaccinations against the human papillomavirus (HPV) have been recommended for the prevention of
cervical cancer. HPV-16/18 AS04-adjuvanted vaccines (Cervarix) are said to have favourable safety pro-
ﬁles. Interstitial lung diseases (ILDs) can occur following exposure to a drug or a biological agent. We
report a case of ILD associated with a Cervarix vaccination. A woman in her 40's, with a history of
conisation, received three inoculations of Cervarix. Three months later, she presented with a cough and
shortness of breath. Findings from a computed tomography of the chest and a transbronchial lung biopsy
were consistent with non-speciﬁc interstitial pneumonia. Workup eliminated all other causes of the ILD,
except for the vaccination. Over the 11 months of the follow-up period, her symptoms resolved without
steroid therapy. The onset and spontaneous resolution of the ILD showed a chronological association
with the HPV vaccination. The semi-quantitative algorithm revealed that the likelihood of an adverse
drug reaction to Cervarix was “Probable”. The outcome was relatively good, but more attention should be
paid to a potential risk for HPV vaccinations to cause ILDs. Wherever possible, chest radiographic ex-
aminations should be performed in order not to overlook any ILDs.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Vaccinations against the human papillomavirus (HPV) have
been recommended for the prevention of cervical cancer [1]. Large-
scale investigations have shown favourable safety proﬁles
regarding HPV-16/18 AS04-adjuvanted vaccines (Cervarix) [2,3]. On
the other hand, adverse effects related to Cervarix are being
registered on online databases [4]. Interstitial lung diseases (ILDs)
can occur following exposure to a drug or a biological agent [5,6].
Vaccines are rarely associated with ILDs, except for some cases of
inﬂuenza [7,8] or BCG vaccines [9]. We report a case of ILD sec-
ondary to the HPV vaccination.
2. Case
2.1. Case presentation
A woman in her 40's presented with a three-month history of a
non-productive cough and shortness of breath. She had no pastashi, Asahikawa, Hokkaido,
Y. Yamamoto).
Ltd. This is an open access article uhistory of pulmonary diseases and dust inhalation. She had quit
smoking 14 years ago, and had not been taking any medication
including over-the-counter drugs, Chinese herbs or supplements.
One year earlier, she had undergone a conisation due to cervical
intraepithelial neoplasia. A pre-operative chest radiograph (Fig. 1a)
and her pulmonary function test results were normal. Two months
after the resection, she had received vaccinations with Cervarix at
0, 1, and 6months. She had no adverse events between the ﬁrst and
third vaccinations. Her symptoms developed three months after
the last vaccination.2.2. Investigations
The physical examination revealed her body temperature to be
37.0 C and ﬁne crackles in chest auscultation, but no clubbing or
skin rashes. Arterial oxy-haemoglobin saturation was 98% with a
heart rate of 70 beats per minutes. A chest radiograph showed
patchy inﬁltrations on both lower lung ﬁelds (Fig. 1b). High-
resolution computed tomography (HRCT) of the chest revealed
peribronchial consolidations, subpleural reticular shadows and
ground glass opacities, all of which were predominantly seen in
both lower lobes (Fig. 2a). Honeycombing and traction bronchiec-
tasis were absent. The radiographic pattern on the HRCT wasnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Chest radiographs before and after HPV vaccinations. The pre-vaccination chest
radiograph (a) has no abnormalities. The post-vaccination chest radiograph (b) shows
patchy inﬁltrations on both lower lung ﬁelds.
Fig. 3. Transbronchial lung biopsy specimen shows alveolar wall thickness with
inﬁltration of inﬂammatory cells.
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scintigram showed a signiﬁcant uptake of 67Ga-citrate into the
diseased areas.
Urinalysis and routine blood test results were normal. Serum
levels of C-reactive protein, anti-nuclear antibodies and Rheuma-
toid factor were within normal range. Biomarkers speciﬁc to ILDs
were elevated in the patient's sera, with Krebs von der Lungen-6
(KL-6) of 2440 U/mL (normal <500 U/mL) and surfactant protein-
D (SP-D) of 135 ng/mL (normal <110 ng/mL). Pulmonary function
tests revealed neither obstructive nor restrictive ventilatory
impairment. Carbon monoxide diffusing capacity fell by 74% from
the predicted value. An arterial blood gas analysis while breathing
room air was normal.
Transbronchial lung biopsy specimens showed inﬁltration of
inﬂammatory cells into thickened alveolar septa (Fig. 3). The
alveolitis was characterised as having chronological homogeneity.
There was no granuloma formation and eosinophil inﬁltration.
These ﬁndings were compatible with the histologic pattern of NSIP.
Total cell counts in the bronchoalveolar lavage ﬂuid (BALF)
increased to 380/mL, which was composed of 55% lymphocytes, 44%
alveolar macrophages, and 1% eosinophils. The ratio of CD4þ/CD8þ
T cells was 1.02. No microorganisms including bacteria, fungi, or
mycobacterium species were identiﬁed from the BALF.2.3. Diagnosis
Any causes presenting with subacute ILDs had to be excluded.
She had no history of inhaling organic dusts, the leading cause of
allergic extrinsic alveolitis. Workup eliminated the possibility of
respiratory infections, eosinophilic lung diseases, sarcoidosis, or
collagen vascular diseases. The ILD was initially diagnosed as
idiopathic NSIP.Fig. 2. High-resolution computed tomography scans. Peribronchial consolidations,
subpleural reticular shadows, and ground glass opacities were seen in both lower lobes
(a). These ﬁndings were reduced over 11 month of the observation period (b).Systemic corticosteroid therapy was scheduled. Unexpectedly,
within a few weeks, her symptoms resolved without the need for
any treatment. The self-limiting course was likely attributed to the
withdrawal of Cervarix. After obtaining her informed consent, we
observed the outcome in an attempt to conﬁrm the temporal as-
sociation with vaccination [6].2.4. Outcome and follow-up
She was restored to full health over 11 months of the follow-up
period. The patchy inﬁltrations in chest radiographs gradually
disappeared with increasing lung volume. HRCT of the chest
showed a reduction in the consolidations (Fig. 2b). Diffusing ca-
pacity also normalised. The likelihood of an adverse drug reaction
(ADR) to Cervarix was estimated using the semi-quantitative Nar-
anjo algorithm [10]. The total scorewas ﬁve, which corresponded to
the “Probable” ADR. The ILD was not life threatening, and did not
result in a persistent disability.3. Discussion
Drug-induced ILDs are referred to as ADRs, which involve the
respiratory system [6]. We identiﬁed ﬁve cases of ILDs associated
with HPV vaccinations (1 Cervarix and 4 Gardasil) in the Vaccine
Adverse Event Reporting System database between 1990 and 2014
[4]. In our case, the likelihood of an ADR was graded as “Probable”
[10].
The clinical manifestations were compatible with inﬂuenza
vaccine-induced ILDs, such as lymphocytosis in the BALF, patho-
logically proven alveolitis and radiographic patterns on HRCT [7,8].
Likewise, biomarkers speciﬁc to ILDs (i.e. KL-6 and SP-D) increased
[8]. The workup eliminated all other causes of the ILD. NSIP often
precedes systemic developments of collagen vascular diseases
[11,12]. However, so far she has been free from any signs of the
disease. For ethical reasons we refrained from a re-challenge test,
the most effective diagnostic procedure for ADRs [6,10]. Therefore,
we cannot conclude that the ILD resulted from a “deﬁnite” ADR to
Cervarix. However, a series of repetitive vaccinations might have
acted as a “natural” re-exposure.
The temporal association with a suspected drug is a crucial
factor for the diagnosis of drug-induced ILDs [6,8]. Obviously, the
ILD developed following a sole exposure to the HPV vaccines. No
other drugs were involved in the disease process. If possible,
corticosteroid use should be avoided with a view to verifying the
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because the patient was free of respiratory distress. The fact that
the ILD improved after the drug was withdrawn possibly suggests
an association with Cervarix.
The Cervarix-associated ILD presumably occurred after the last
vaccination, and it peaked at the time of diagnosis. In general,
exposure to a drug can induce ILDs with various latencies [5,6]. We
failed to determine the onset precisely because the HRCT scans had
not been checked before and during the vaccination period. Inﬂu-
enza vaccines can induce ILDs with latencies ranging from 1 to 10
days [7,8]. In contrast, the ILD in this case developed three months
after the last vaccination. The latency appeared longer than those of
inﬂuenza vaccines [8]. Possible mechanism(s) may include direct
toxic effects, T cell-mediated immune responses, or both [5,6].
Nevertheless, three doses of Cervarix were unlikely to exert
persistent cytotoxic effects on the lungs. Instead, the presence of
the lymphocytic alveolitis suggested that cell-mediated immunity
was attributed to the development of ILDs. BCG vaccines can also
cause ILDs through Mycobacterium bovis dissemination [9]. This
was unlikely because Cervarix is a non-infectious recombinant
vaccine [13e15].
The most likely explanation is that repetitive vaccinations might
have sensitised the patient's immune system. Unlike inﬂuenza and
BCG vaccines, Cervarix contains the AS04 adjuvant that exhibits
strong immunogenicity [13e15]. The compound itself might have
been an offending antigen to the lungs. We speculate that the pa-
tient became sensitive to Cervarix during the course of the ﬁrst two
vaccinations. This probably led to the development of ILD after the
ﬁnal vaccination. To date, AS04-adjuvanted vaccines have not been
associated with new onset of chronic diseases or autoimmune
disorders [2,3,13e15]. Unfortunately, the list of these conditions
does not contain any types of ILDs. Further studies are needed to
clarify the prevalence of ILDs in vaccinated subjects.
The Cervarix-associated ILD showed a mild clinical manifesta-
tion, and did not result in a persistent disability. This was probably
because the patient was relatively young and free from co-
morbidity. In contrast, inﬂuenza vaccines can induce ILDs more
often in elderly patients [7,8]. Pre-existing lung diseases may in-
crease the risk of developing ILDs [8]. Severe ILDs can develop after
pandemic inﬂuenza-A vaccinations [8]. However, in most cases,
steroid therapy can achieve a good response, leading to a preferable
clinical outcome [7,8]. Vaccine-induced ILDs are difﬁcult to recog-
nize because vaccines have rarely been reported as causative
agents. Therefore, noticing the probability of ADRs to vaccines is
important to make the appropriate intervention.
There is little doubt, if any, of the efﬁcacy and safety of HPV
vaccines [2,3]. The aim of this case report was not to focus on the
negative aspects of Cervarix, but to attract more attention to un-
expected complications in the lungs. When those who have been
inoculated complain of persisting respiratory symptoms, chest
radiographic assessments are required. Moreover, the ILD devel-
oped independently of its known risks such as high age and pre-
existing pulmonary lesions [5,6]. This is noteworthy becausehealthy young women are the most common demographic to
receive the HPV vaccination [1,2].
4. Conclusions
Cervarix is an effective and safe vaccine, but may have a risk to
cause ILDs. Wherever possible, chest radiographic examinations
should be performed in order not to overlook any ILDs.
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